From 1 August 2026, nitisinone (Orfadin®) will become available through the Pharmaceutical Benefits Scheme (PBS) for the treatment of hereditary tyrosinaemia type 1 (HT1) under certain conditions.
New patients commencing treatment with Orfadin® from 1 August will access their treatment through the PBS rather than the Life Saving Drugs Program (LSDP).
Patients currently receiving Orfadin® through the LSDP will transition to accessing their treatment through the PBS by 1 November 2026. Transitional arrangements will be in place to support patients during this change.
The LSDP has advised that information about the transition has been provided to treating physicians and pharmacies currently involved in providing Orfadin®.
People currently receiving Orfadin® are encouraged to read the patients factsheet and speak with their treating metabolic team if they have questions about how the change may affect them.
Further information is also available through the PBS website or the LSDP website.
This information is based on advice provided to MDDA by the Australian Government Life Saving Drugs Program.